Completed PHASE2 INTERVENTIONAL 2-arm NCT01377974

Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis

Randomized Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis at Federal District, Brazil

Sponsor: Brasilia University Hospital

Conditions Leishmaniasis Leishmaniasis, Mucocutaneous

Interventions Miltefosine Standard Treatment Meglumine antimoniate

Updated 6 times since 2017 Last updated: Jun 8, 2015 Started: Jul 31, 2009 Primary completion: Jun 30, 2013 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01377974, this PHASE2 trial focuses on Leishmaniasis and Leishmaniasis, Mucocutaneous and remains completed. Sponsored by Brasilia University Hospital, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Brasilia University Hospital

Data source: Brasilia University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brasília, Brazil